Search Results - "Gavilondo, Jorge V"

Refine Results
  1. 1

    Antibody engineering at the millennium by Gavilondo, J V, Larrick, J W

    Published in BioTechniques (01-07-2000)
    “…It has been almost 100 years since von Behring and Kitasato received the first Nobel prize for the discovery of passive immunotherapy and nearly 25 years since…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4
  5. 5

    Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: From bench to bedside by Morera-Díaz, Yanelys, Gavilondo, Jorge V., Bequet-Romero, Mónica, Sánchez Ramírez, Javier, Hernández-Bernal, Francisco, Selman-Housein, Katty-Hind, Perez, Lincidio, Ayala-Ávila, Marta

    Published in Seminars in oncology (01-01-2018)
    “…HEBERSaVax is a cancer therapeutic vaccine candidate based on the combination of a recombinant antigen representative of human vascular endothelial growth…”
    Get full text
    Journal Article
  6. 6

    CIGB-247: A VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors by Bequet-Romero, Mónica, Morera, Yanelys, Ayala-Ávila, Marta, Ancizar, Julio, Soria, Yordanka, Blanco, Aracelys, Suárez-Alba, Jesús, Gavilondo, Jorge V

    Published in Vaccine (27-02-2012)
    “…Highlights ► Antimetastatic effects of a VEGF based active immunotherapy: CIGB-247. ► CIGB-247 is a cancer therapeutic, based on recombinant modified VEGF as…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9
  10. 10

    Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates by Morera, Yanelys, Bequet-Romero, Mónica, Ayala, Marta, Pérez, Pedro Puente, Castro, Jorge, Sánchez, Javier, Alba, José Suárez, Ancízar, Julio, Cosme, Karelia, Gavilondo, Jorge V

    Published in Vaccine (05-01-2012)
    “…Highlights ► CIGB-247 is a cancer therapeutic, based on recombinant modified VEGF as antigen, in combination with powerful adjuvant VSSP. ► We extend the…”
    Get full text
    Journal Article
  11. 11

    Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates by Morera, Yanelys, Bequet-Romero, Mónica, Ayala, Marta, Velazco, Jorge Castro, Pérez, Pedro Puente, Alba, Jesús Suárez, Ancizar, Julio, Rodríguez, Meilyn, Cosme, Karelia, Gavilondo, Jorge V

    Published in Vaccine (26-04-2010)
    “…Abstract We have developed a cancer vaccine candidate (hereafter denominated CIGB-247), based on recombinant modified human vascular endothelial growth factor…”
    Get full text
    Journal Article
  12. 12
  13. 13

    Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants by Morera, Yanelys, Bequet-Romero, Mónica, Ayala, Marta, Lamdán, Humberto, Agger, Else-Marie, Andersen, Peter, Gavilondo, Jorge V.

    Published in Angiogenesis (London) (01-12-2008)
    “…Following the clinical success of Bevacizumab, a humanized monoclonal antibody that affects the interaction between vascular endothelial growth factor (VEGF)…”
    Get full text
    Journal Article
  14. 14

    Experimental studies of a vaccine formulation of recombinant human VEGF antigen with aluminum phosphate by Pérez Sánchez, Lincidio, Morera Díaz, Yanelys, Bequet-Romero, Mónica, Ramses Hernández, Gerardo, Rodríguez, Yadira, Castro Velazco, Jorge, Puente Pérez, Pedro, Ayala Avila, Marta, Gavilondo, Jorge V

    Published in Human vaccines & immunotherapeutics (03-08-2015)
    “…CIGB-247 is a cancer vaccine that is a formulation of a recombinant protein antigen representative of the human vascular endothelial growth factor (VEGF) with…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    Transient expression in tobacco leaves of an aglycosylated recombinant antibody against the epidermal growth factor receptor by Rodriquez, M, Ramirez, N.I, Ayala, M, Freyre, F, Perez, L, Triguero, A, Mateo, C, Selman-Housein, G, Gavilondo, J.V, Pujol, M

    Published in Biotechnology and bioengineering (20-01-2005)
    “…When generating stably transformed transgenic plants, transient gene expression experiments are especially useful to rapidly confirm that the foreign molecule…”
    Get full text
    Journal Article
  18. 18
  19. 19

    Efficient construction of a highly useful phage-displayed human antibody repertoire by Rojas, Gertrudis, Lamdan, Humberto, Padron, Sheila, Munoz, Yasmiana, Ayala, Marta, Gavilondo, Jorge V.

    “…We have constructed a highly useful phage-displayed human antibody repertoire with limited cloning efforts. Our strategy was to maximize diversity during the…”
    Get full text
    Journal Article
  20. 20

    Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice by BEQUET-ROMERO, Monica, AYALA, Marta, ACEVEDO, Boris E, GALBAN RODRIGUEZ, Ernesto, LOPEZ OCEJO, Omar, TORRENS, Isis, GAVILONDO, Jorge V

    Published in Angiogenesis (London) (01-03-2007)
    “…Passive immunotherapy against soluble pro-angiogenic factors and/or their receptors in endothelial cells has become a promising approach in cancer…”
    Get full text
    Journal Article